Private company

Inozyme Pharma, Inc.

In its 2025 annual report the company says: “We are a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. It is well established that low levels of PPi drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases.”4 It is headquartered in Boston, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address321 Summer Street, Suite 400, Boston, Ma 022102
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our expertise lies in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate ("PPi"), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). It is well established that low levels of PPi drive pathologic mineralization and low levels of adenosine drive intimal proliferation in a number of rare diseases. Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament ("OPLL").4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56789-$104.0M in 2024+400% since 2019
-$150.0M-$100.0M-$50.0M02019: -$20.8M-$20.8M20192020: -$57.0M-$57.0M2020+174%2021: -$56.6M-$56.6M2021−1%2022: -$68.7M-$68.7M2022+21%2023: -$75.6M-$75.6M2023+10%2024: -$104.0M-$104.0M2024+38%
Net income56789-$102.0M in 2024+417% since 2019
-$150.0M-$100.0M-$50.0M02019: -$19.7M-$19.7M20192020: -$56.4M-$56.4M2020+186%2021: -$56.6M-$56.6M2021+0%2022: -$67.1M-$67.1M2022+18%2023: -$71.2M-$71.2M2023+6%2024: -$102.0M-$102.0M2024+43%
Fiscal year20182019202020212022202320242025
Research and development$16.2M5$46.5M6$37.7M7$47.8M8$54.8M9$83.2M9
Operating expenses$56.6M7$68.7M8$75.6M9$104.0M9
Operating income-$20.8M5-$57.0M6-$56.6M7-$68.7M8-$75.6M9-$104.0M9
Interest$262.0K8$3.3M8
Income tax$05$06$07$08$09$09
Net income-$19.7M5-$56.4M6-$56.6M7-$67.1M8-$71.2M9-$102.0M9
Earnings per share-$2.407-$1.788-$1.379-$1.629
Earnings per share (diluted)-$2.407-$1.788-$1.379-$1.629
Shares (weighted, basic)23.6M shares737.8M shares851.8M shares962.8M shares9
Shares (weighted, diluted)23.6M shares737.8M shares851.8M shares962.8M shares9

Compare Inozyme Pharma, Inc. with another company

Corporate structure

Inozyme Pharma, Inc. sits at the top of its group. 4 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Inozyme Pharma, Inc.

  • Pivotal bioVenture Partners Fund I, L.P. Filed SCHEDULE 13D/A on Inozyme Pharma, Inc., latest Aug 27, 2025 (7 filings since Feb 14, 2022)
  • Beryl Capital Management LLC Filed SCHEDULE 13G/A on Inozyme Pharma, Inc., latest Aug 14, 2025 (2 filings since May 23, 2025)
  • Rock Springs Capital Management LP Filed SCHEDULE 13G/A on Inozyme Pharma, Inc., latest Aug 13, 2025 (4 filings since Apr 25, 2022)
  • Adage Capital Management, L.P. Filed SCHEDULE 13G/A on Inozyme Pharma, Inc., latest Aug 12, 2025
  • GLAZER CAPITAL, LLC Filed SCHEDULE 13G on Inozyme Pharma, Inc., latest Jun 4, 2025
  • Affinity Asset Advisors, LLC Filed SCHEDULE 13G/A on Inozyme Pharma, Inc., latest May 30, 2025 (2 filings since Dec 9, 2024)
  • EVENTIDE ASSET MANAGEMENT, LLC Filed SCHEDULE 13G/A on Inozyme Pharma, Inc., latest Apr 23, 2025 (3 filings since Feb 14, 2024)
  • SAMLYN CAPITAL, LLC Filed SCHEDULE 13G/A on Inozyme Pharma, Inc., latest Feb 14, 2025 (2 filings since Feb 14, 2024)
  • BlackRock Filed SC 13G on Inozyme Pharma, Inc., latest Nov 8, 2024 (2 filings since Oct 24, 2024)
  • Sofinnova Venture Partners X, L.P. Filed SC 13D/A on Inozyme Pharma, Inc., latest Feb 20, 2024
  • BAKER BROS. ADVISORS LP Filed SC 13G/A on Inozyme Pharma, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Deep Track Capital, LP Filed SC 13G/A on Inozyme Pharma, Inc., latest Feb 14, 2024 (3 filings since Apr 18, 2022)
  • Inozyme Pharma, Inc. Boston, Massachusetts
    • Inozyme Pharma Ireland Limited Subsidiary · Ireland
    • Inozyme Pharma Switzerland GmbH Subsidiary · Switzerland
    • Inozyme Securities Corp. Subsidiary · Massachusetts, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Inozyme Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.9M9 Dec 31, 2024$3.9M9 Dec 31, 2023+1.5%
Accumulated depreciation$3.2M9 Dec 31, 2024$2.4M9 Dec 31, 2023+30.7%
Property and equipment, net$784.0K9 Dec 31, 2024$1.5M9 Dec 31, 2023−46.5%
Operating-lease assets (leased space)$562.0K9 Dec 31, 2024$1.1M9 Dec 31, 2023−50.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$21.1M9 Dec 31, 2024$34.6M9 Dec 31, 2023−39.1%
Marketable securities, current$92.0M9 Dec 31, 2024$154.0M9 Dec 31, 2023−40.3%
Debt securities available for sale$92.0M9 Dec 31, 2024$154.0M9 Dec 31, 2023−40.3%
Long-term investments$09 Dec 31, 2024$08 Dec 31, 2023

Properties, in its own words

Our principal facilities consist of office and laboratory space in Boston, Massachusetts. We occupy approximately 8,499 square feet of office space under a lease that expires in October 2025. In addition, we occupy approximately 6,244 square feet of laboratory space under a lease that expires in December 2025. We do not own any real property. We believe that this office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.

Item 2 of the 10-K filed Mar 10, 2025.4

Leadership

Who has led Inozyme Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Axel Bolte2021–2022
  2. Douglas A. Treco2023–now

Chair

  1. Douglas A. Treco2025–now

Chief financial officer

  1. Stephen J. Dipalma2021
  2. Sanjay Subramanian2022–now

Chief operating officer

  1. Henric Bjorn Bjarke2021–2022
  2. Matthew Winton2023–now
2025
Board members and other officers (15)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Inozyme Pharma Ireland Limited Ireland3
  • Inozyme Pharma Switzerland GmbH Switzerland3
  • Inozyme Securities Corp. Massachusetts3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Inozyme Pharma, LLCJan 5, 2017 to Jan 5, 20172

Timeline

  1. Jul 1, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer34
  2. Jun 23, 20258-K Other events35
  3. Jun 2, 20258-K Executive or director change36
  4. May 16, 20258-K Entered a material agreement; Regulation FD disclosure37
  5. May 14, 20258-K Completed an acquisition or sale38
  6. Mar 10, 20258-K Results of operations; Exit or restructuring costs39
  7. Jan 10, 20258-K Results of operations; Regulation FD disclosure; Other events40
  8. Nov 5, 20248-K Results of operations41
  9. Oct 24, 20248-K Regulation FD disclosure; Other events42
  10. Oct 7, 20248-K Completed an acquisition or sale43
  11. Aug 6, 20248-K Results of operations44
  12. Aug 6, 20248-K Other events45
  13. Apr 4, 2023New chief executive Douglas A. Treco becomes CEO13
  14. Jan 14, 2021New chief executive Axel Bolte becomes CEO14

Calendar

When it reported results

  1. Mar 10, 2025Reported quarterly or annual results39
  2. Jan 10, 2025Reported quarterly or annual results40
  3. Nov 5, 2024Reported quarterly or annual results41
  4. Aug 6, 2024Reported quarterly or annual results44
  5. May 7, 2024Reported quarterly or annual results46
  6. Mar 12, 2024Reported quarterly or annual results47
  7. Aug 8, 2023Reported quarterly or annual results48
  8. Jul 26, 2023Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

223 filings to the SEC since October 2021: 5 annual reports, 11 quarterly reports, 42 major events, 72 insider forms, 48 large holders, 45 other. The latest 20:

  1. Aug 27, 2025SCHEDULE 13D/A EDGAR
  2. Aug 14, 2025SCHEDULE 13G/A EDGAR
  3. Aug 13, 2025SCHEDULE 13G/A EDGAR
  4. Aug 12, 2025SCHEDULE 13G/A EDGAR
  5. Jul 11, 202515-12G EDGAR
  6. Jul 3, 20254 EDGAR
  7. Jul 3, 20254 EDGAR
  8. Jul 3, 20254 EDGAR
  9. Jul 3, 20254 EDGAR
  10. Jul 3, 20254 EDGAR
  11. Jul 3, 20254 EDGAR
  12. Jul 1, 2025EFFECT EDGAR
  13. Jul 1, 2025EFFECT EDGAR
  14. Jul 1, 2025S-8 POS EDGAR
  15. Jul 1, 2025S-8 POS EDGAR
  16. Jul 1, 2025S-8 POS EDGAR
  17. Jul 1, 2025S-8 POS EDGAR
  18. Jul 1, 2025S-8 POS EDGAR
  19. Jul 1, 2025S-8 POS EDGAR
  20. Jul 1, 2025POS AM EDGAR

The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 14 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 2, 2025Treco Douglas ACEO & ChairmanSale8,819$0.89$7.8KForm 4
Apr 2, 2024Treco Douglas ACEO & ChairmanSale7,523$6.94$52.2KForm 4
Aug 1, 2023Pivotal bioVenture Partners Fund I, L.P.DirectorBuy833,333$4.80$4.0MForm 4
Aug 1, 2023Hopfner Robert LorneDirectorBuy833,333$4.80$4.0MForm 4
May 12, 2023Hopfner Robert LorneDirectorBuy228,702$6.25$1.4MForm 4
May 11, 2023Hopfner Robert LorneDirectorBuy219,230$6.48$1.4MForm 4
Mar 29, 2023Hopfner Robert LorneDirectorBuy344,592$4.54$1.6MForm 4
Mar 28, 2023Hopfner Robert LorneDirectorBuy156,766$4.16$652.1KForm 4
Mar 27, 2023Hopfner Robert LorneDirectorBuy51,074$3.70$189.0KForm 4
Dec 15, 2022Bjarke Henric BjornSVP, COOBuy21,500$1.39$29.9KForm 4
Apr 19, 2022Hopfner Robert LorneDirectorBuy1,070,000$3.69$3.9MForm 4
Apr 19, 2022Bjarke Henric BjornSVP, COOBuy27,100$3.69$100.0KForm 4
Apr 19, 2022Bolte AxelDirectorBuy67,750$3.69$250.0KForm 4
Apr 19, 2022Subramanian SanjaySVP, CFO & Head of BDBuy27,100$3.69$100.0KForm 4
Apr 19, 2022Pivotal bioVenture Partners Fund I U.G.P., LtdDirectorBuy1,070,000$3.69$3.9MForm 4
Apr 19, 2022Longitude Capital Partners III, LLC10% ownerBuy1,355,000$3.69$5.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Douglas A. TrecoPh.D.$541.7K$2.5M71
2024Matthew WintonPh.D.$456.8K$1.8M71
2024Sanjay S. Subramanian$462.0K$1.7M71
2023Chief Executive Officer and Chariman$375.0K$5.3M71
2023Senior VicePresident and Chief Financial Officer and Head of Business Development$444.3K$1.0M71

SEC filer profile

How Inozyme Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARInozyme Pharma, Inc.1
  • CIK0001693011
  • Employer ID (EIN)38-40245284
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address321 Summer Street, Suite 400, Boston, MA 022101
  • Phone857-330-43401
  • Shares outstanding64,561,824 as of Apr 30, 202512
  • Public float$199.3B as of Jun 28, 20244
  • AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJan 5, 20171
  • Filings378 in all: 4 (120), 8-K (51), 3 (34), SC 13G/A (19), SC 13G (17), 10-Q (15), SC 13D/A (11), CORRESP (8)1
    All 44 form types

    UPLOAD (8), SCHEDULE 13G/A (7), DEFA14A (6), S-8 (6), S-8 POS (6), 10-K (5), D/A (5), DEF 14A (5), EFFECT (5), SC 13D (5), 424B5 (4), SC TO-T/A (4), ARS (3), S-1/A (3), SC 14D9/A (3), SC TO-C (3), D (2), POS AM (2), S-3 (2), SC14D9C (2), SCHEDULE 13G (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), S-1 (1), S-1MEF (1), SC 14D9 (1), SC TO-T (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 10, 2025
    Quarterly report (10-Q) May 14, 2025
    Proxy statement (DEF 14A) Apr 29, 2025
    Latest 8-K (8-K) Jul 1, 2025

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.0001 per shareINZYNasdaq Global Select Market

From the cover page of the 10-K filed Mar 10, 2025 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Inozyme Pharma, Inc. names in Item 1A of its 10-K filed Mar 10, 2025: 72 risks under these headings, as written.4

  • Risks Related to our Financial Position and Need for Additional Capital
  • We have incurred significant losses since our inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future and may never achieve or maintain profitability.
  • We have never generated revenue from product sales and may never achieve or maintain profitability.
  • We are heavily dependent on the success of our lead product candidate, INZ-701, which will require significant clinical testing before we can seek marketing approval and potentially launch commercial sales. If INZ-701 does not receive marketing approval or is not successfully commercialized, or if there is significant delay in doing so, our business will be harmed.
  • We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  • We have a loan agreement that requires us to meet specified funding conditions for future draw downs and operating covenants and places restrictions on our operating and financial flexibility.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.
  • We hold a portion of our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts, and our liquidity and operations could be adversely affected if a financial institution holding such funds fails.
  • Changes in tax laws or in their implementation may adversely affect our business and financial condition.
  • Our ability to use our NOLs and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.
  • Risks Related to Research and Development of our Product Candidates
The other 62 risks
  • We are early in our clinical development efforts. If we are unable to commercialize INZ-701 or experience significant delays in doing so, our business will be materially harmed.
  • Because we are developing INZ-701 for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to predict or provide clinically meaningful results.
  • If we experience delays or difficulties in the enrollment of patients in our clinical trials for INZ-701 or any other product candidate we develop, our receipt of necessary marketing approvals could be delayed or prevented.
  • If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of INZ-701 or any other product candidate we may develop, we may need to abandon or limit our further clinical development of those product candidates.
  • Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.
  • If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We are conducting clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from clinical trials conducted in such locations.
  • Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.
  • Adverse public perception of genetic medicine, and gene therapy in particular, may negatively impact regulatory approval of, or demand for, our potential products.
  • Risks Related to the Commercialization of our Product Candidates
  • Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.
  • If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market.
  • If the market opportunities for our product candidates are smaller than we currently believe, our revenue may be adversely affected, and our business may suffer. Because the target patient populations of our product candidates are small, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.
  • Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.
  • Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business.
  • Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Risks Related to our Dependence on Third Parties
  • We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.
  • Manufacturing biologic products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.
  • We may enter into collaborations with third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.
  • If we are not able to establish or maintain collaborations, we may have to alter our development and commercialization plans and our business could be adversely affected.
  • We have agreements with Yale to supplement our internal research and development program. If Yale decides to discontinue or devote less resources to such research, our research efforts could be diminished.
  • Any acquisitions or in-license transactions that we complete could disrupt our business, cause dilution to our stockholders or reduce our financial resources.
  • Risks Related to our Intellectual Property
  • If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.
  • Our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.
  • If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.
  • Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • Although we or our licensors are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.
  • We may not be able to protect our intellectual property and proprietary rights throughout the world.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Intellectual property rights do not necessarily address all potential threats.
  • Risks Related to Regulatory Approval and Other Legal Compliance Matters
  • Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process of the FDA, the EMA and comparable foreign authorities is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we develop, and our ability to generate revenue will be materially impaired.
  • Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.
  • Fast track designation, breakthrough therapy designation and/or priority review designation by the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates.
  • Accelerated approval by the FDA or comparable foreign regulatory authorities, even if granted for our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
  • We may not be able to obtain or maintain orphan drug exclusivity for INZ-701 or any other product candidates we develop for one or more indications, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.
  • We may seek a Rare Pediatric Disease Designation for one or more of our product candidates. However, a BLA for one or more of our product candidates may not meet the eligibility criteria for a priority review voucher upon approval.
  • The FDA, EMA, or other comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our product development strategy and we may not realize the commercial potential of any such product candidate.
  • Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.
  • Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.
  • Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
  • Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our product candidates and affect the prices we, or they, may obtain.
  • The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions, which could impact the prices we obtain for our products, if approved.
  • Inadequate funding for the FDA, the SEC, and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.
  • Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing, and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.
  • If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.
  • Risks Related to Employee Matters and Managing Growth
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • We expect to expand our development and regulatory capabilities and potentially implement sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors, or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
  • Our employees, independent contractors, including principal investigators, consultants and vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.
  • Risks Related to our Common Stock
  • Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.
  • Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.

Legal proceedings

We are not currently a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71